High dose versus standard dose statins in stable coronary heart disease

UBC Faculty Research and Publications

High dose versus standard dose statins in stable coronary heart disease Therapeutics Initiative (University of British Columbia)

Description

Therapeutics Letter 87 examines high dose versus standard dose statins in stable coronary heart disease. Conclusions: In patients with stable CHD who tolerate a standard dose of a statin: High dose statins do not reduce mortality as compared to standard dose statins, RR 0.99 [0.93, 1.06]. High dose statins reduce non-fatal MI as compared to standard dose statins, RR 0.83 [0.76, 0.91], ARR 1.2%, but this is not reflected in a reduction in total SAEs, RR 1.00 [0.98, 1.01]. In women high dose statins numerically increased total mortality, RR 1.32 [0.90, 1.92] and numerically reduced non fatal MI, RR 0.75 [0.50, 1.13] as compared to standard dose statins. High dose statins increased withdrawals due to adverse effects, RR 1.45 [1.34,1.58], ARI 2.5%, as compared to standard dose statins. Because of the lack of effect on mortality and total SAEs there is no net health benefit from prescribing high dose statins over standard dose statins.

Item Metadata

Title	High dose versus standard dose statins in stable coronary heart disease
Alternate Title	Therapeutics Letter 87
Creator	Therapeutics Initiative (University of British Columbia)
Date Issued	2012-08
Description	Therapeutics Letter 87 examines high dose versus standard dose statins in stable coronary heart disease. Conclusions: In patients with stable CHD who tolerate a standard dose of a statin: High dose statins do not reduce mortality as compared to standard dose statins, RR 0.99 [0.93, 1.06]. High dose statins reduce non-fatal MI as compared to standard dose statins, RR 0.83 [0.76, 0.91], ARR 1.2%, but this is not reflected in a reduction in total SAEs, RR 1.00 [0.98, 1.01]. In women high dose statins numerically increased total mortality, RR 1.32 [0.90, 1.92] and numerically reduced non fatal MI, RR 0.75 [0.50, 1.13] as compared to standard dose statins. High dose statins increased withdrawals due to adverse effects, RR 1.45 [1.34,1.58], ARI 2.5%, as compared to standard dose statins. Because of the lack of effect on mortality and total SAEs there is no net health benefit from prescribing high dose statins over standard dose statins.
Subject	Coronary Disease; Drug-Related Side Effects and Adverse Reactions; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iatrogenic Disease
Genre	Other
Type	Text
Language	eng
Notes	The UBC TI is funded by the BC Ministry of Health to provide evidence-based information about drug therapy. We neither formulate nor adjudicate provincial drug policies.
Date Available	2023-06-20
Provider	Vancouver : University of British Columbia Library
Rights	Attribution-NonCommercial-NoDerivatives 4.0 International
DOI	10.14288/1.0433666
URI	http://hdl.handle.net/2429/85076
Affiliation	Medicine, Faculty of; Anesthesiology, Pharmacology and Therapeutics, Department of
Peer Review Status	Reviewed
Scholarly Level	Faculty; Researcher
Rights URI	http://creativecommons.org/licenses/by-nc-nd/4.0/
Aggregated Source Repository	DSpace

Open Collections

UBC Faculty Research and Publications